Work

Exploration of safety indicators for radiotherapy in hepatocellular carcinoma: A real-world study.

Year: 2025

Type: article

Abstract: OBJECTIVES: as a radiotherapy safety dose indicator based on real-world data, as well as to explore the safety and efficacy of EBRT in HCC. METHODS: . Radiotherapy-related hepatitis virus reactivation and other radiotherapy-related toxicities were also observed. Progression-free survival (PFS) and overall survival (OS) were used to evaluate the efficacy of EBRT in HCC. RESULTS: =0.88). One patient without regular anti-hepatitis viral treatment was diagnosed with radiotherapy-related HBV clinical reactivation, and one patient was diagnosed with immunotherapy-related HBV clinical reactivation. The median PFS was 5.6 months in the IMRT group and 16.4 months in the SBRT group, and the best local control rates were 98.6% and 100.0%, respectively. The median OS was 12.2 months in the IMRT group and 33.5 months in the SBRT group. The 6-month, 1-year, and 2-year OS rates in the IMRT group were 77.1%, 52.6%, and 18.6%, respectively. The 1-year, 2-year, 3-year, 4-year, and 5-year OS rates in the SBRT group were 86.1%, 61.7%, 39.2%, 25.7%, and 18.3%, respectively. CONCLUSIONS: /SLV may be more reliable for evaluating the occurrence of RILDs after IMRT treatment. For patients with hepatitis background, concurrent antiviral therapy during radiotherapy is relatively safe, but serum viral load should be closely monitored. Further research is needed to explore the efficacy and safety of radiotherapy combined with targeted and immunotherapy.

Source: PubMed

DOI: 10.11817/j.issn.1672-7347.2025.250218